妊娠合并瓣膜性心脏病心脏事件风险分层工具的验证
本研究在中收入国家三级中心连续纳入577例妊娠合并瓣膜性心脏病患者,验证DEVI和CARPREG-II对不良心脏复合事件的预测效能。69例(12.1%)发生复合终点,DEVI的AUC为0.884(95%CI:0.844-0.923),CARPREG-II为0.808(95%CI:0.753-0.863);两模型在10%-50%预测概率阈值区间均有临床效用,DEVI预测与观察事件一致性更好。
要点
- 妊娠合并VHD患者中DEVI和CARPREG-II均具有良好的区分度和临床效用。
- DEVI的AUC为0.884,CARPREG-II为0.808,DEVI预测与观察事件一致性更好。
- 两模型在10%-50%预测概率阈值区间内决策曲线分析显示有临床效用。
核心结论
- 在妊娠合并瓣膜性心脏病患者中,DEVI和CARPREG-II评分均显示出良好的区分能力和临床效用。
- DEVI评分在预测概率与观察事件之间的一致性更好。
研究设计与样本
- 研究为队列研究,纳入2019年1月至2022年4月期间在中收入国家三级中心连续收治的妊娠合并瓣膜性心脏病患者。
- 共577例合格妊娠纳入分析,使用DEVI和CARPREG-II模型计算个体不良复合心脏事件风险。
- 通过区分度和校准特征评估模型性能,并使用决策曲线分析评估临床效用。
主要发现
- 577例妊娠中69例(12.1%)发生复合终点事件。
- 94.7%的患者为风湿性病因,二尖瓣反流为主要病变(48.2%)。
- DEVI的AUC为0.884(95%CI:0.844-0.923),CARPREG-II的AUC为0.808(95%CI:0.753-0.863)。
- 校准图提示DEVI评分在较高预测概率时高估风险,CARPREG-II评分在两端高估风险、中间概率低估风险。
- 决策曲线分析显示两模型在10%至50%预测概率阈值区间内均有临床效用。
关键数值与推荐
- DEVI的AUC为0.884(95%CI:0.844-0.923),CARPREG-II的AUC为0.808(95%CI:0.753-0.863)。
- 复合终点事件发生率为12.1%(69/577例妊娠)。
- 风湿性病因占94.7%,二尖瓣反流占48.2%。
- 决策曲线分析显示两模型在10%至50%预测概率阈值区间内均有临床效用。
临床怎么用
- 对于妊娠合并瓣膜性心脏病患者,可使用DEVI或CARPREG-II评分进行不良心脏事件风险分层。
- DEVI评分预测概率与观察事件一致性更好,在较高预测概率时需注意其可能高估风险。
- 两模型在10%至50%预测概率阈值区间内具有临床效用,可辅助临床决策。
局限性
- 研究为单中心队列,结果外推需谨慎。
- 人群以风湿性病因为主,可能限制对其他病因人群的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most risk stratification tools for pregnant patients with heart disease were developed in high-income countries and in populations with predominantly congenital heart disease, and therefore, may not be generalizable to those with valvular heart disease (VHD). OBJECTIVES: The purpose of this study was to validate and establish the clinical utility of 2 risk stratification tools-DEVI (VHD-specific tool) and CARPREG-II-for predicting adverse cardiac events in pregnant patients with VHD. METHODS: We conducted a cohort study involving consecutive pregnancies complicated with VHD admitted to a tertiary center in a middle-income setting from January 2019 to April 2022. Individual risk for adverse composite cardiac events was calculated using DEVI and CARPREG-II models. Performance was assessed through discrimination and calibration characteristics. Clinical utility was evaluated with Decision Curve Analysis. RESULTS: Of 577 eligible pregnancies, 69 (12.1%) experienced a component of the composite outcome. A majority (94.7%) had rheumatic etiology, with mitral regurgitation as the predominant lesion (48.2%). The area under the receiver-operating characteristic curve was 0.884 (95% CI: 0.844-0.923) for the DEVI and 0.808 (95% CI: 0.753-0.863) for the CARPREG-II models. Calibration plots suggested that DEVI score overestimates risk at higher probabilities, whereas CARPREG-II score overestimates risk at both extremes and underestimates risk at middle probabilities. Decision curve analysis demonstrated that both models were useful across predicted probability thresholds between 10% and 50%. CONCLUSIONS: In pregnant patients with VHD, DEVI and CARPREG-II scores showed good discriminative ability and clinical utility across a range of probabilities. The DEVI score showed better agreement between predicted probabilities and observed events.
引用
- Pande SN, Yavana Suriya J, Ganapathy S, et al. Validation of Risk Stratification for Cardiac Events in Pregnant Women With Valvular Heart Disease. J Am Coll Cardiol. 2023. PMID: 37758434. doi:10.1016/j.jacc.2023.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。